BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additional treatment. Activating mutations in KRAS or BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Chui, M. Herman, Kjaer, Susanne K., Frederiksen, Kirsten, Hannibal, Charlotte G., Wang, Tian-Li, Vang, Russell, Shih, Ie-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901340/
https://www.ncbi.nlm.nih.gov/pubmed/31839880
http://dx.doi.org/10.18632/oncotarget.27326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901340/
https://www.ncbi.nlm.nih.gov/pubmed/31839880
http://dx.doi.org/10.18632/oncotarget.27326

Ejemplares similares